This module enables investors to look at Juno Therapeutics various fundamental indicators over time in order to gain insight into the company future performance. Macroaxis historical fundamental analysis tools allow evaluation of not only typical financial statement drivers such as Gross Profit of 111.9 M, Operating Expenses of 308.6 M or Preferred Dividends Income Statement Impact of 79.4 M, but also many exotic indicators such as Long Term Debt to Equity of 0.0096, Cash Flow Per Share of 0.0886 or Revenue to Assets of 0.0148. This module is a perfect complement to use when analyzing Juno Therapeutics Valuation or Volatility. It can also complement various Juno Therapeutics Technical models. Please also check Risk vs Return Analysis.